Genfit
(NASDAQ: GNFT)
|
5:30 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $3.97 | Change: +0.00 | %Change: +0.00% | Volume: 1,198 |
Open: | $ 3.96 | Volume: | 1,198 | |
---|---|---|---|---|
High: | $ 3.98 | Yield(%) | 0.00 | |
Low: | $ 3.94 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 197.54M | |
EPS ($) | n/a | Shares Out: | 49.76M |
% Price Change (last 4 weeks): | -26.74 |
---|---|
% Price Change (last 13 weeks): | 11.20 |
% Price Change (last 26 weeks): | -1.49 |
% Price Change (last 52 weeks): | 6.15 |
% Price Change (year to date): | 3.12 |
Return on Equity (%): | -35.74 |
---|---|
Return on Assets (%): | -14.84 |
Return on Invested Capital (%): | -13.88 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | -101.15 |
Operating Profit Margin (%): | -127.97 |
|
|
50-day Moving Average: | $4.18 |
---|---|
200-day Moving Average: | $3.65 |
Avg. Daily Vol. (last 50 days): | 28,062 |
Avg. Daily Vol. (last 200 days): | 19,217 |
52-wk high: | $6.05 |
52-wk low: | $2.89 |
Bid: | $3.84 |
Ask: | $3.99 |
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.
|
Genfit
Parc Eurasante 885, Avenue Eugène Avinée Lille Métropole Loos HF 59120 Phone: 33.3.20.16.40.00 Fax: 33.3.20.16.40.01 http://www.genfit.com |
Earnings (1year) ($): | -0.63 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 1.50 |
Cash Flow ($): | -0.59 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 6.20 |
Price/Book (x): | 2.57 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 2.94 |
---|---|
Current Ratio (x): | 2.94 |
LT Debt/Equity (x): | 92.33 |
Total Debt/Equity (x): | 104.08 |